Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release

Abstract

Cancer cell expresses abundant surface receptors. These receptors are important targets for cancer treatment and imaging applications. Our goal here is to develop nanoparticles with cargo loading and tumor targeting capability. Methods: A peptide targeting at cancer cell surface receptor (urokinase receptor, uPAR) was expressed in fusion with albumin (diameter of ~7 nm), and the fusion protein was assembled into nanoparticles with diameter of 40 nm, either in the presence or absence of cargo molecules, by a novel preparation method. An important feature of this method is that the nanoparticles were stabilized by hydrophobic interaction of the fusion protein and no covalent linking agent was used in the preparation. The stability, the cargo release, in vitro and in vivo properties of such formed nanoparticles were characterized by transmission electron microscopy, dynamic light scattering, gel shift assay, laser scanning confocal microscopy and 3D fluorescent molecular tomography. Results: The nanoparticles were stable for more than two weeks in aqueous buffer, even in the buffer containing 10% fetal bovine serum. Interestingly, in the presence of urokinase receptor, the uPAR-targeting nanoparticle disintegrated into 7.5 nm fragments and released its cargo, but not the non-targeting nanoparticles made from albumin by the same preparation method. Such nanoparticles also showed higher uptake and cytotoxicity to the receptor-expressing cancer cells in vitro and higher tumor accumulation in xenografted tumor-bearing mice in vivo compared to the non-targeting nanoparticles. Conclusion: Our results demonstrate a new function of cell surface receptor as a responsive trigger to disassemble nanoparticles, besides its common use to enrich targeting agents. Such nanoparticles were thus named receptor-responsive nanoparticles (RRNP).

Therapeutics targeting the fibrinolytic system

“…In our recent work, we formulated ATF-HSA into a nanoparticle to encapsulate a larger amount of ZnPc photosensitizer (Fig. 2d) 125 . This ATF-HSA nanoparticle is able to disintegrate by contacting uPAR on the tumor surface and release ZnPc, leading to a potent photodynamic effect.…”

Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy

“…Overexpression of uPA is an important hallmark of many cancers. Its substrate specificity, that is, exclusively breaking the Arg-Ser bond in the Ser-Gly-Arg-Ser-Ala sequence of substrate peptides 165 , contributes to the successful development of uPA-controlled tumor penetrating peptide 166 and fusion protein-based NPs 167 for effective drug loading and protease-driven payload delivery in tumor lesion. In order to achieve the super-early detection and good prognosis of pancreatic ductal adenocarcinoma (PDAC), a Gd 3+ -based MRI contrast agent and cyanine dye Cy5.5 were combined with U11 (a pancreatic cancer-specific peptide) to form a dual-modal MRI/NIR FI nanoprobe for highly sensitive and spatially resolved detection of pancreatic precancerosis 168 .…”

Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer

“…One group developed a fusion protein containing the urokinase receptor targeting agent and β-carboxy phthalocyanine zinc (ZnPc-COOH) (CPZ) to target urokinase-type plasminogen activator receptor (uPAR), which is overexpressed in many invasive carcinomas. NPs were used for delivery of the fusion protein to H22 mouse hepatocellular carcinoma cell line tumors in mice, resulting in tumor growth inhibition [189].…”